trial

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

NCTId NCT03437668
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Terminated
Enrollment 47 (actual)
Sponsored by Chengappa, K.N. Roy, MD
Primary completion 2023-06-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Terminated
Enrollment
47 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2018-12-01
Primary completion
2023-06-12
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
WSE

Sponsors

Chengappa, K.N. Roy, MDLead Sponsor
Stanley Medical Research InstituteCollaborator
University of Maryland, Baltimore CountyCollaborator

Investigators

1
Stephen R. Marder, MDStudy Chair

Sites

2 total
Los Angeles, United StatesCatonsville, United States

Linked catalysts

1
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People Wi — primary completion2023-06-12

Facts & assertions

4 sourced
Enrollment
47
Phase
PHASE2,PHASE3
Primary Completion Date
2023-06-12
Status
TERMINATED
relationships
The graph out of here
drug
WSE
drug
lead_sponsor
Chengappa, K.N. Roy, MD
company
collaborator
Stanley Medical Research Institute
company
University of Maryland, Baltimore County
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Stephen R. Marder, MD
person